Hirotsugu Kenmotsu
Shizuoka Cancer Center · 561 works · 8,348 citations · h-index 42
Top works
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer
- Efficacy of gefitinib for non‐adenocarcinoma non‐small‐cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports
- Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer
- Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study
- Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer
- Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
- Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer
- Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure
- The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
- Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
- IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
- Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System
- Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial
- Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
- High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy
- Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single‐institute study
- LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer.
- Microcavity Array System for Size-Based Enrichment of Circulating Tumor Cells from the Blood of Patients with Small-Cell Lung Cancer
- Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure